Brentuximab before transplant for relapsed CD30 Hodgkin lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies whether brentuximab vedotin given in the “second-line” setting can help people with relapsed or hard-to-treat classic Hodgkin lymphoma get ready for an autologous (your own cells) stem cell transplant. It’s specifically for tumors that test positive for CD30, and it checks safety and how well treatment works before transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have classical Hodgkin lymphoma that is CD30-positive on a pathology test
- You are 18 to 65 years old
- You have disease that can be measured, such as a lymph node or mass at least 1.5 cm
- Your nervous system nerve symptoms are mild: no neuropathy of grade 2 or higher
- You have completed prior treatments enough time ago to be eligible (no very recent chemo/experimental drugs)
- You do not have certain infections, brain/nerve conditions, or specific hepatitis/HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether pembrolizumab plus brentuximab works better than standard chemotherapy followed by an autologous stem cell transplant for people whose classic Hodgkin lymphoma has come back or did not respond. It may help by improving cancer control before and around stem cell transplant and by comparing outcomes between the two treatment approaches.
This trial tests a combination of two targeted drugs, chidamide and brentuximab vedotin, for people with a type of T-cell lymphoma that has the CD30 protein. It is for patients who are older or not healthy enough for standard chemotherapy, and whose cancer has come back or not responded to previous treatment.
This study looks at how well brentuximab vedotin works for adults with Hodgkin’s lymphoma who have either already had, or are being considered for, stem cell transplant. It may help people who are receiving a specific treatment plan to control the lymphoma after transplant planning.
This Phase 2 trial studies brentuximab vedotin plus nivolumab in people whose classical Hodgkin lymphoma has come back or did not respond to treatment. It aims to shrink tumors and improve control of the disease, especially when standard options like transplant are not possible.
This study tests a treatment plan for adults with Hodgkin lymphoma that has returned or did not respond to ABVD chemotherapy. It may help people with a higher-risk pattern of disease, as long as their organ function and overall health meet study limits.
This trial is a survey study that looks at how brentuximab vedotin is used in children with Hodgkin lymphoma. It focuses on people whose tumor is CD30-positive and who have not had prior treatment, to see how the drug fits with a standard chemotherapy plan (AVD).
Hear when a new Hodgkin Lymphoma, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.